Welcome to our dedicated page for 4D Molecular Therapeutics SEC filings (Ticker: FDMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) SEC filings page provides access to the company’s regulatory disclosures as a public issuer. These documents include current reports on Form 8-K, periodic reports and other filings that describe clinical progress, material agreements, capital raises, governance changes and stockholder actions.
For investors tracking 4D Molecular Therapeutics’ gene therapy programs, Form 8-K filings are particularly relevant. Recent 8-Ks have covered topics such as interim clinical data from the PRISM Phase 1/2 trial of 4D-150 in wet age-related macular degeneration, updates on the AEROW trial of 4D-710 in cystic fibrosis lung disease, the collaboration and license agreement with Otsuka Pharmaceutical for 4D-150 in Asia-Pacific markets, and the appointment or transition of key executives and directors. Other 8-Ks report on equity offerings, preliminary cash and investment balances, and amendments to corporate bylaws.
Filings also disclose that 4D Molecular Therapeutics’ common stock trades on the Nasdaq Global Select Market under the symbol FDMT, and they provide details on matters submitted to stockholder votes, such as director elections, auditor ratification and advisory votes on executive compensation and its frequency.
On Stock Titan, these SEC filings are updated in near real time from the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key terms of collaboration and license agreements, explain the implications of financing transactions, and surface important information about clinical data disclosures, governance changes and cash runway guidance. Users can also review filings that relate to equity offerings, including underwriting agreements and pre-funded warrants, and examine how these transactions fit into 4D Molecular Therapeutics’ overall development and funding strategy.
4D Molecular Therapeutics reported two corporate governance updates. The Board appointed Ashoo Gupta, age 49, as the company’s Principal Financial Officer and Principal Accounting Officer, effective September 30, 2025. He has been Vice President, Finance & Controller since June 2024 and previously held senior finance and controller roles at Kyverna Therapeutics and Myovant Sciences. He will enter into the company’s standard indemnification agreement.
The Board also approved amended and restated bylaws on September 30, 2025. The changes include updates to the advance notice procedures for stockholder proposals of business and for the nomination of directors at meetings. The full text of the amended and restated bylaws is filed as an exhibit and incorporated by reference.
4D Molecular Therapeutics (FDMT) Form 144: The filing notifies a proposed sale of 7,312 common shares with an aggregate market value of $54,108.80, to be sold on or about 09/23/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The filing lists total outstanding shares of 46,702,467, which places the proposed sale at a de minimis percentage of the outstanding float. The shares were acquired in two transactions: 4,905 shares from an exercise of stock options on 09/23/2025 and 2,407 shares through the employee stock purchase plan on 11/14/2022; payment was in cash. No other sales in the past three months were reported. The filer certifies no undisclosed material adverse information at the time of signing.
4D Molecular Therapeutics reported heavy R&D investment and widening losses for the quarter and six months ended June 30, 2025. The company held $77.2 million in cash and $339.9 million in total marketable securities (current and long-term), for total assets of $473.6 million, which management says is sufficient to fund planned operations for at least one year. Net loss was $54.7 million for the quarter and $102.6 million for the six-month period, driven by R&D expense of $47.95 million in the quarter and $88.65 million for six months. Operating cash used was $91.1 million for the six months. Accumulated deficit totaled $678.8 million and basic/diluted net loss per share was $(0.98) for the quarter and $(1.84) for six months. Subsequent events note a workforce reduction of approximately 25% with estimated cash exit costs of $3.0 million (with $0.9 million recorded).
4D Molecular Therapeutics announced that it furnished a press release reporting its financial results for the three months ended June 30, 2025. The Form 8-K references a press release titled "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" as Exhibit 99.1 and includes an interactive data file as Exhibit 104. The company’s common stock trades on the Nasdaq Global Select Market under the ticker FDMT. The filing itself does not include numerical financial details in the text provided here; investors must consult Exhibit 99.1 for the full results and operational highlights.
Form 4 overview: On 06/17/2025, 4D Molecular Therapeutics, Inc. (FDMT) granted director Jacob Chacko a stock option covering 22,500 common shares at an exercise price of $4.15 per share. The filing lists no sales or open-market purchases of the company’s equity; the only transaction disclosed is the option award delivered under the company’s non-employee director compensation program.
Vesting terms: One-third of the option becomes exercisable on 06/17/2026, with the remainder vesting in equal monthly installments until fully vested on 06/17/2028. The award also accelerates to 100% vesting upon a Change in Control, as defined in FDMT’s 2020 Incentive Award Plan.
Ownership impact: Following the grant, Chacko’s derivative-security holdings rise to 22,500 options. No non-derivative common-stock holdings are reported in Table I, suggesting the director currently holds no directly owned FDMT shares or that such holdings were unchanged.
Investor takeaway: The transaction is a routine equity-based compensation grant aimed at aligning director incentives with shareholder interests. It does not involve cash outlay by the company today, carries a 10-year life (expiring 06/16/2035), and is unlikely to materially affect FDMT’s share count or near-term financials.
Form Type: Form 4
Company: 4D Molecular Therapeutics, Inc. (FDMT)
Reporting Person: Susannah Gray, independent director
On 17 June 2025, Ms. Gray received an automatic non-employee director stock-option grant covering 22,500 shares of FDMT common stock. The option has an exercise price of $4.15 per share, identical to the market price on the grant date under the company’s equity plan. No shares were purchased or sold on the open market; the filing merely records the award of a derivative security.
Vesting schedule:
- 1/3 of the option (7,500 shares) vests on 17 June 2026.
- The remaining 15,000 shares vest in equal monthly installments through 17 June 2028.
- Accelerated vesting applies if a Change in Control (per the 2020 Incentive Award Plan) occurs before full vesting.
Following the grant, Ms. Gray’s beneficial ownership in derivative securities totals 22,500 options, all held directly. No other equity transactions (purchases, sales, or disposals) were reported, and the filing does not reference any open-market activity or additional holdings.
The filing is routine for director compensation and does not include earnings data, cash transactions, or changes in company fundamentals. Investors should view it largely as an administrative disclosure of annual board compensation rather than a signal of trading intent.
4D Molecular Therapeutics (FDMT) filed a Form 4 reporting that director Shawn Cline Tomasello received an automatic, non-employee director stock-option grant on 06/17/2025.
The award comprises 22,500 stock options with an exercise price of $4.15. Vesting occurs as follows: one-third on 06/17/2026, with the remaining two-thirds vesting in equal monthly installments through 06/17/2028. All options vest immediately upon a change-in-control, and they expire on 06/16/2035. The filing shows 22,500 derivative securities beneficially owned after the transaction. No open-market acquisitions or dispositions of common shares were reported.
4D Molecular Therapeutics (FDMT) – Form 4 filing: Director Charles Theuer received an automatic grant of 22,500 stock options on 17 June 2025 under the company’s non-employee director compensation program.
The options carry a $4.15 exercise price and a 10-year term expiring 16 June 2035. Vesting is staggered: 33% on 17 June 2026, with the balance vesting in equal monthly installments through 17 June 2028. All unvested shares vest immediately if a change-in-control occurs.
After the grant, the reporting person holds 22,500 derivative securities directly. No open-market purchases or sales were reported, and there were no changes in non-derivative holdings. The disclosure is routine and primarily reflects standard director equity compensation designed to align incentives with shareholder interests.
Form 4 filing for 4D Molecular Therapeutics (FDMT) reports a routine non-derivative insider transaction dated 06/17/2025.
- Reporting person: Nancy Miller-Rich, independent director.
- Transaction: Automatic grant of 22,500 stock options (right to buy common shares) at an exercise price of $4.15 per share.
- Vesting schedule: 1/3 vests on 06/17/2026; the remainder vests monthly until fully vested on 06/17/2028, or sooner upon a change-of-control event.
- Expiration: 06/16/2035.
- Post-transaction holdings: 22,500 derivative securities reported as directly held.
No sales or purchases of already-issued common stock occurred, and the filing contains no financial performance data. The grant stems from the company’s standard non-employee director compensation program and does not indicate a shift in corporate strategy or insider sentiment.
FAQ
What is the current stock price of 4D Molecular Therapeutics (FDMT)?
What is the market cap of 4D Molecular Therapeutics (FDMT)?
